BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)

NCT00523328 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2016-01-21

No results posted yet for this study

Summary

This study is to observe the long-term treatment of BG9924

Conditions

Interventions

DRUG

BG9924

dosage administered as per Biogen-idec protocol

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States
  • Belgium
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00523328 on ClinicalTrials.gov